E
Exelixis, Inc. (EXEL)
NMS – Real vaqt narxi. Valyuta: USD
49.46
-0.25 (-0.50%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
49.46
-0.25 (-0.50%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Exelixis, Inc. — bu onkologiya kompaniyasi bo'lib, Qo'shma Shtatlarda davolash qiyin bo'lgan saraton turlari uchun yangi dori vositalarini kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya ilgari anti-angiogenik terapiya olgan bemorlarda ilg'or buyrak hujayrali karsinomani davolash uchun CABOMETYX planshetlarini; va progressiv va metastatik medullulyar qalqonsimon bez saratonini davolash uchun COMETRIQ kapsulalarini taklif etadi. Uning CABOMETYX va COMETRIQ preparatlari MET, AXL, RET va VEGF retseptorlari, shu jumladan ko'plab tirozinkinazlar ingibitori bo'lgan kabozantinibdan olingan. Kompaniya, shuningdek, ilg'or melanomaning ma'lum turlarini davolash uchun kombinatsiyalangan rejim sifatida MEK ingibitori bo'lgan COTELLICni; va Yaponiyada gipertenziyani davolash uchun mineralkortikoid retseptorining og'zaki steroid bo'lmagan selektiv blokeri bo'lgan MINNEBROni taklif etadi. U TAM kinazlari, MET va VEGF retseptorlari, shu jumladan kinazlarning yangi, kuchli og'zaki ingibitori bo'lgan zanzalintinibni; BRCA-mutatsiyali o'smalar kontekstida sintez qilinadigan halokatli maqsad bo'lgan USP1 ning kichik molekulyar ingibitori bo'lgan XL309ni; 5T4 o'simta antigeniga yo'naltirilgan monoklonal antiteloga kon'yugatsiyalangan MMAE yukiga ega bo'lgan antitelodori kon'yugati (ADC) bo'lgan XB010ni; dastlabki sinfga mansub va dastlabki hujayra o'limi ligand 1 va tabiiy killer hujayra retseptorlari guruhi 2A ni nishonga olgan bispesifik antitelosi bo'lgan XB628ni; va topoisomerase ingibitori yukiga ega bo'lgan keyingi avlod to'qima omilini nishonga olgan ADC bo'lgan XB371ni ishlab chiqmoqda. Kompaniya Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; va Daiichi Sankyo Company, Limited bilan tadqiqot hamkorliklari va litsenziya shartnomalariga ega, shuningdek, biznesni rivojlantirish faoliyati va boshqa hamkorliklarni amalga oshiradi. Kompaniya ilgari Exelixis Pharmaceuticals, Inc. nomi bilan tanilgan va 2000-yil fevral oyida Exelixis, Inc. nomini o'zgartirgan. Exelixis, Inc. 1994-yilda tashkil etilgan va shtab-kvartirasi Kaliforniyaning Alameda shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Brenda J. Hefti J.D., Ph.D. | Senior VP & General Counsel |
| Dr. Dana T. Aftab Ph.D. | Executive Vice President of Research & Development |
| Dr. Michael M. Morrissey Ph.D. | CEO, President & Director |
| Dr. Stefan Krauss Ph.D. | VP & Head of Business Development |
| Dr. Stelios Papadopoulos Ph.D. | Co-Founder & Independent Chair of the Board |
| Dr. William Berg M.D. | Senior Vice President of Medical Affairs |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 8-K | exel-20260505.htm |
| 2026-05-05 | 10-Q | exel-20260403.htm |
| 2026-04-17 | DEFA14A | exelixis-proxysupplementcl.htm |
| 2026-04-15 | DEF 14A | exel-20260415.htm |
| 2026-02-10 | 8-K | exel-20260210.htm |
| 2026-02-10 | 10-K | exel-20260102.htm |
| 2026-01-12 | 8-K | exel-20260111.htm |
| 2025-11-07 | 8-K | exel-20251104.htm |
| 2025-11-04 | 10-Q | exel-20251003.htm |
| 2025-08-29 | 8-K | exel-20250829.htm |
| Mr. Andrew Ross Peters | Senior Vice President of Strategy |
| Mr. Christopher J. Senner | Executive VP & CFO |
| Mr. Patrick Joseph Haley M.B.A. | Executive Vice President of Commercial |
| Ms. Deborah Burke CPA | Senior VP of Finance & Controller |